HC Wainwright Estimates Oncobiologics FY2030 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Oncobiologics in a research report issued on Friday, January 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.13) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share.

Oncobiologics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, December 19th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The firm had revenue of $4.65 million during the quarter, compared to analyst estimates of $5.85 million.

Other research analysts also recently issued research reports about the company. Ascendiant Capital Markets lifted their price target on Oncobiologics from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Wall Street Zen cut Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncobiologics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Oncobiologics Stock Down 17.8%

OTLK opened at $0.54 on Monday. The stock has a fifty day moving average of $1.69 and a 200-day moving average of $1.65. The firm has a market capitalization of $34.79 million, a P/E ratio of -0.36 and a beta of 0.17. Oncobiologics has a 12-month low of $0.50 and a 12-month high of $3.39.

Institutional Investors Weigh In On Oncobiologics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC raised its position in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after acquiring an additional 25,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares in the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.